Abstract: Applicators for grasping and applying small items, such as fibers and eyelashes, are disclosed. The applicators passively hold the items and a user actuates the applicator to release the items. An applicator includes a compression spring that forces a disc against a disc retention element to hold the items passively, and a button is pressed to separate the disc from the disc retention element to release the items. An applicator includes an expansion spring that holds items between coils of the spring passively, and a button is pressed to separate the spring coils to release the items.

Abstract: The present invention relates to a new cosmetic or pharmaceutical composition charactrized in that it comprises at least on vitamin component chosen from the group consisting of vitamin C and its derivatives, vitamin A (or retinol) and its derivatives, and mixtures of these components, in association with at least one fucose component chosen form the group consisting of fucose, polysacharides and oligosaccharides that contain fucose, sisting of fucose, polysaccharides and oligosaccharides that contain fucose, and mixtures of these components, as well as at least one acceptable excipient. This composition enables one to reduces significantly, by means of a real synergy effect, the toxic effect of the vitamin component and, therefore, to use in the composition contents of the vitamin component higher or equal to the contents of the products that already exist on the market without any risk for the user.

Abstract: The present invention relates to a mixture of non-sulfated fucose-based oligosaccharides, characterized in that it comprises oligosaccharides of less than 13 saccharide units, comprising at least one fucose unit in a non-reducing end position, and in that at least it is capable of being obtained by means of a process that comprises at least one step of degradation of a polysaccharide from a microorganism of the gender Klebsiella pneumoiae subsp. pneumoniae. This new mixture presents significant activities on different components of the skin, providing a clearly visible anti-aging result, specially by an excellent thickening of the skin.

Abstract: A process for the preparation of a catalyst is described, said catalyst comprising at least one inorganic refractory support, at least one halogen or halogenated compound at a content greater than 0.1% by weight, at least one metal from group VIII of the periodic classification (platinum, palladium, nickel and ruthenium) and at least one additional metal M selected from germanium, tin, lead, iron, titanium and chromium. The process is characterised in that said metal M is introduced in the form of at least one orqanometallic complex. The catalyst prepared in accordance with the invention may be used for dehydrogenation reactions, particularly of paraffinic hydrocarbons and olefinic hydrocarbons.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents alkyl,R.sub.2, R.sub.4 and R.sub.5, which may be identical or different, represent hydrogen or alkyl,R.sub.3 represents any one of the groups as defined in the description,X represents carbonyl or methylene,Y represents hydrogen or alkyl or aryl,A represents single bond or alkylphenyl,R.sub.6 represents any one of the groups as defined in the description, its isomers as well as its addition salts with a pharmaceutically acceptable acid or base,and medicinal productes containing the same are useful in the treatment of diabetes and complications of diabetic disease.

Abstract: A compound selected from those of formula (I): ##STR1## where m is equal to 0 or 1 and Het, A, X, R,R.sub.1, R.sub.2, R.sub.3, R.sub.4 and the ring ##STR2## are defined in the description, and a medicinal product comprising the same for treating an inflammatory disorder.

Abstract: A compound selected from those of formula (I): ##STR1## where m is equal to 0 or 1andHet, A, X, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and the ring ##STR2## are defined in the description, and a medicinal product comprising the same for treating an inflammatory disorder.

Abstract: A method of treating a mammal afflicted with a disorder associated with the Na.sup.+ -independent Cl.sup.- /HCO.sub.3 - exchanger comprising the step of administering a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and n are as defined in the description, which is effective for alleviating the said disorder.

Abstract: Compounds of the general formula: ##STR1## wherein m, X, Y, A, R.sub.2 and R.sub.3 are defined in the description, and medicaments containing the same.

Abstract: Compounds of the general formula: ##STR1## wherein m, X, Y, A, R.sub.2 and R.sub.3 are defined in the description.

Abstract: Process for the dehydrogenation of a charge incorporating saturated aliphatic hydrocarbons essentially having 3 to 5 carbon atoms per molecule, in which the charge, previously heated to the reaction temperature and without premixing with the hydrogen, is introduced at the inlet of at least one reactor, where the dehydrogenation reaction is performed in the presence of a catalyst, preferably incorporating a support having at least one oxide of an element chosen from among the groups IIA, IIB, IIIA, IIIB, IVA and IVB of the periodic classification of elements, at least one noble metal from the platinum family, at least one promotor metal and at least one alkali metal or alkaline earth metal.

Abstract: A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.

Abstract: A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.